GlassScriptPhysician profile
Farida Esaa Hakim
NPI 1952898520
$957.78
in general payments reported to CMS, 2019-2025
7 companies · $62.97 in 2025
The $62.97 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $124 · 2021: $239 · 2022: $125 · 2024: $35.05 · 2025: $62.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $343.64 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $201.02 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $143.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $123.64 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $98.02 | 2024-2025 | |
| Iridex Corporation | $41.06 | 2020 | |
| New World Medical,INC. | $6.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farida Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.